Colgate Palmolive Co (CL) · Oct 30, 2026 · Earnings
Beat — Diluted EPS $0.94 vs ~$0.93 consensus; base-business EPS $0.97
Colgate-Palmolive’s Q3 earnings narrowly beat consensus, while stronger margins and EPS guidance lifted the full-year outlook despite weak North American volumes.
Colgate-Palmolive is in the middle of its 2030 growth strategy, leaning on premium innovation, brand investment, emerging-market expansion and Hill’s Pet Nutrition while trying to recover volumes in North America. Its prior-quarter story was already improving: worldwide organic volume had increased sequentially for a third straight quarter, but North America remained the weak spot.
The quarter cleared a modest market bar. Net sales of $5.369 billion exceeded the published consensus of roughly $5.34 billion, while diluted EPS of $0.94 topped consensus near $0.93. That is a narrow earnings beat, not a blowout, but the underlying result was better than the headline GAAP number: base-business EPS reached $0.97, up 7% year over year. The published consensus figures are externally sourced; the company’s reported results are from the filing. 〔0〕
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net sales (Financial Highlights) | $5,369 (+4.6%) | $5,131 | ~$5,340 |
| Organic sales growth (Financial Highlights) | 3.6% | — | — |
| Diluted EPS, GAAP (Financial Highlights) | $0.94 (+3%) | $0.91 | ~$0.93 |
| Base-business diluted EPS (Financial Highlights) | $0.97 (+7%) | $0.91 | — |
| Operating margin, base business (Operating Profit by Division) | 20.8% (+20 bps) | 20.6% | — |
Management raised the more important full-year framework. Organic sales growth is now expected to track the first nine months, implying roughly 3%, versus the prior 1%-4% range; GAAP and base-business gross margins are now expected to rise rather than remain roughly flat; and base-business EPS growth is now expected at 5%-7%, up from “mid-single-digit” growth. 〔1〕 〔2〕
The quality of growth improved, but the geography remains uneven. Total-company organic sales rose 3.6%, with volume contributing 1.7% and pricing 2.0%, while Latin America grew organic sales 12.5% and Hill’s Pet Nutrition 5.6%. North America, however, saw organic sales fall 1.6%, including a 3.7% volume decline, and its operating profit dropped 11% with a 210-basis-point margin contraction. That keeps the central execution problem intact even as the global portfolio performs well. 〔3〕
Margins and cash generation support the upgrade. Base-business operating margin expanded 20 basis points despite another double-digit advertising increase, and nine-month free cash flow before dividends rose to $2.513 billion from $2.358 billion. The improvement is meaningful because Colgate is funding brand investment and restructuring while still reducing debt less cash to $6.104 billion from $6.947 billion a year earlier. The caveat is that reported nine-month operating profit remains down 5% because of the Strategic Growth and Productivity Program, so the cleaner base-business trend is doing most of the work in the outlook.
Bottom line: This is better than a routine in-line quarter: Colgate beat a modest consensus bar and raised its full-year margin and EPS framework. The upgrade strengthens the global growth-and-productivity story, but North America’s volume weakness remains the unresolved drag on the business.
Q3 earnings call, October 30
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!